Quantum Leap Grant Analysis ### 📋 Eligible Entities - Canadian biopharmaceutical companies (public and private) - Small and medium-sized enterprises (SMEs) in the life sciences sector - Research institutions partnered with commercial entities - Domestic drug discovery and development organizations - Organizations must have a Canadian presence and operations - Eligible entities typically must demonstrate capability to commercialize innovations ### 💰 Funding Details - Grant Amount: Variable based on project scope and organizational size (typically $100,000–$2,000,000+) - Matching Requirements: Often requires cost-sharing from applicant (typically 25–50% match depending on company size and stage) - Repayability: Non-repayable grant (subject to program terms; some programs may have royalty-based recovery clauses) - Funding Structure: Direct project-based grants; funds disbursed in tranches upon milestone completion - No collateral required for grant component ### 🛠️ Approved Expenses - R&D Payroll: Salaries for researchers, scientists, and technical staff directly engaged in eligible projects - Technology & Equipment: Computational tools, laboratory equipment, and platforms for drug discovery - Software & Platforms: Digital solutions and proprietary systems for development processes - Clinical Trial Support: Costs associated with preclinical and clinical validation studies - Intellectual Property: Patent filing, licensing, and technology acquisition - Contractor Services: Specialized consulting and outsourced R&D services - Materials & Supplies: Lab consumables and research materials directly tied to project - Travel: Conference attendance and collaborative research meetings (typically limited) ### ⚠️ Conditions & Milestones - Project Timeline: Typically 2–5 years with defined milestones and reporting checkpoints - Milestone-Based Disbursement: Funds released upon achievement of agreed deliverables (e.g., prototype development, validation results, IP filings) - Quarterly/Annual Reporting: Mandatory progress reports demonstrating R&D advancement and fund utilization - IP Ownership: Canadian government retains certain